Should Pharma Companies Give Up Discovery Research?
9/11/2013 8:27:33 AM
A little while back, a fellow Forbes contributor, David Shaywitz, tweeted the following provocative statement: “My ? based on Onyx deal and others: should med/large pharmas just give up all pretense of R & early D (a la Andrew Baum), move explicitly 2 S&D.” Shaywitz is not some yahoo attacking the pharma industry’s R&D capabilities. He is a distinguished physician-scientist with both big pharma and biotech experience. Thus, when someone like him questions the wisdom of pharma investing in early research, it deserves some soul searching.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by